Dive Brief:
- Tandem Diabetes Care has received Food and Drug Administration clearance for its Mobi tubeless automated insulin delivery system.
- The authorization, which Tandem disclosed Friday, sets the company up for a 2027 launch of a device that will challenge Insulet for the tubeless pump market. Tandem will also now be competing in the tubeless market with MiniMed, which announced FDA clearance for its tubeless insulin pump Monday morning.
- Tandem’s Mobi tubeless pump is “the company’s single most important commercial catalyst and growth driver,” Leerink Partners analysts said in a note to investors.
Dive Insight:
Tubed pumps deliver insulin via a tube connected to an infusion set. Tandem has turned its tubed Mobi pump into a tubeless design by replacing the infusion set with a disposable on-body kit. Users can choose to wear it as a tubed or tubeless pump.
Tandem plans to enter the tubeless pump market next year. The company committed to the launch window after receiving FDA clearance for a new infusion set and cartridge for Mobi, which is cleared for up to seven days of wear.
William Blair analysts expect “a relatively smooth transition to Mobi tubeless.” Tandem should see “little pausing of current Mobi new customer growth” because the core device remains the same, the analysts said in a note to investors. Patients interested in the new product can buy the tubed Mobi device and switch to the tubeless infusion set and cartridge when they come to market.
Patients could switch to Mobi tubeless from rival devices, Leerink analysts said. The analysts’ prediction reflects their belief that the device has “advantages in form factor and pharmacy access.” Patients who currently rely on multiple daily injections to manage their diabetes may also switch to Mobi tubeless, the analysts said.
Tandem plans a limited launch before expanding to full commercial availability in the first half of next year, William Blair analysts said. The rollout will allow the company to build manufacturing capacity and update pharmacy contracts. Tandem will make tubeless supplies available exclusively via the pharmacy for customers with pharmacy benefits.
The company estimates that Mobi pharmacy coverage is available for about 50% of insured lives in the U.S. and expects expansion before and after the launch.
Tandem leaders believe payers and pharmacy benefit managers see Mobi tubeless as an important addition to the pharmacy channel, making the device “a lever in coverage discussions,” William Blair analysts said.